World journal of gastrointestinal oncology · 2025
Effect of antiviral therapy on 3-year recurrence and prognosis of hepatocellular carcinoma after curative radiofrequency ablation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Bai-Guo, Zhang Xue, Liu Fang, Li Feng-Hui, Zhang Xu, Xiang Hui-Ling, Liang Jing
Аннотация
BACKGROUND: The impact of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF) on long-term recurrence and overall survival in patients with hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) who undergo curative radiofrequency ablation (RFA) remains unclear.
AIM: To compare the 3-year recurrence and survival rates among HCC patients receiving these three first-line oral anti-hepatitis B virus (anti-HBV) agents after RFA.
METHODS: This retrospective cohort study included patients with hepatitis B cirrhosis who were initially diagnosed with HCC at Tianjin Third Central Hospital, China, from August 2018 to December 2020, and had complete clinical data. All patients were followed up for at least 144 weeks. Cox regression analysis was performed to identify independent risk factors for HCC recurrence. Recurrence-free survival was analyzed using Kaplan-Meier curves, and Cox regression models were constructed after adjusting for gamma-glutamyl transferase, alpha-fetoprotein, and Barcelona Clinic Liver Cancer staging.
RESULTS: A total of 319 patients receiving oral anti-HBV therapy were divided into three groups: ETV group (n = 191), TDF group (n = 76), and TAF group (n = 52). At 6 and 12 months, there were no significant differences in recurrence rates between the groups. However, at 24 and 36 months, the TDF and TAF groups exhibited significantly lower recurrence rates compared with the ETV group [24 months: TDF, hazard ratio (HR) = 0.51, 95% confidence interval (CI): 0.29-0.91, P = 0.022; TAF, HR = 0.54, 95%CI: 0.28-1.03, P = 0.046; 36 months: TDF, HR = 0.57, 95%CI: 0.35-0.93, P = 0.025; TAF, HR = 0.54, 95%CI: 0.31-0.96, P = 0.037]. The 3-year mortality rates were similar across the three groups (ETV: 21.47%, TDF: 18.42%, TAF: 23.08%; P = 0.790).
CONCLUSION: Among patients with hepatitis B cirrhosis-related HCC, TDF and TAF are associated with lower 2-year and 3-year HCC recurrence rates after curative RFA treatment compared with ETV. However, there were no significant differences in 3-year mortality rates between the ETV, TDF, and TAF groups.
AIM: To compare the 3-year recurrence and survival rates among HCC patients receiving these three first-line oral anti-hepatitis B virus (anti-HBV) agents after RFA.
METHODS: This retrospective cohort study included patients with hepatitis B cirrhosis who were initially diagnosed with HCC at Tianjin Third Central Hospital, China, from August 2018 to December 2020, and had complete clinical data. All patients were followed up for at least 144 weeks. Cox regression analysis was performed to identify independent risk factors for HCC recurrence. Recurrence-free survival was analyzed using Kaplan-Meier curves, and Cox regression models were constructed after adjusting for gamma-glutamyl transferase, alpha-fetoprotein, and Barcelona Clinic Liver Cancer staging.
RESULTS: A total of 319 patients receiving oral anti-HBV therapy were divided into three groups: ETV group (n = 191), TDF group (n = 76), and TAF group (n = 52). At 6 and 12 months, there were no significant differences in recurrence rates between the groups. However, at 24 and 36 months, the TDF and TAF groups exhibited significantly lower recurrence rates compared with the ETV group [24 months: TDF, hazard ratio (HR) = 0.51, 95% confidence interval (CI): 0.29-0.91, P = 0.022; TAF, HR = 0.54, 95%CI: 0.28-1.03, P = 0.046; 36 months: TDF, HR = 0.57, 95%CI: 0.35-0.93, P = 0.025; TAF, HR = 0.54, 95%CI: 0.31-0.96, P = 0.037]. The 3-year mortality rates were similar across the three groups (ETV: 21.47%, TDF: 18.42%, TAF: 23.08%; P = 0.790).
CONCLUSION: Among patients with hepatitis B cirrhosis-related HCC, TDF and TAF are associated with lower 2-year and 3-year HCC recurrence rates after curative RFA treatment compared with ETV. However, there were no significant differences in 3-year mortality rates between the ETV, TDF, and TAF groups.